The Therapeutic Potential of Abcirximab (c7E3 Fab) in Percutaneous Transluminal Coronary Angioplasty

Abcirximab (c7E3 Fab) is a chimaeric mouse/human antibody fragment that binds specifically to the platelet receptor for fibrinogen and von Willebrand factor, preventing platelet aggregation. It is potentially useful for the treatment of thrombotic arterial diseases and for the prevention of thrombotic complications of coronary artery disease or its therapy.